Your browser doesn't support javascript.
loading
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
De Henau, Olivier; Rausch, Matthew; Winkler, David; Campesato, Luis Felipe; Liu, Cailian; Cymerman, Daniel Hirschhorn; Budhu, Sadna; Ghosh, Arnab; Pink, Melissa; Tchaicha, Jeremy; Douglas, Mark; Tibbitts, Thomas; Sharma, Sujata; Proctor, Jennifer; Kosmider, Nicole; White, Kerry; Stern, Howard; Soglia, John; Adams, Julian; Palombella, Vito J; McGovern, Karen; Kutok, Jeffery L; Wolchok, Jedd D; Merghoub, Taha.
Afiliación
  • De Henau O; Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory, New York, New York 10065, USA.
  • Rausch M; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Winkler D; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Campesato LF; Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory, New York, New York 10065, USA.
  • Liu C; Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory, New York, New York 10065, USA.
  • Cymerman DH; Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory, New York, New York 10065, USA.
  • Budhu S; Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory, New York, New York 10065, USA.
  • Ghosh A; Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory, New York, New York 10065, USA.
  • Pink M; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Tchaicha J; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Douglas M; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Tibbitts T; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Sharma S; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Proctor J; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Kosmider N; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • White K; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Stern H; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Soglia J; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Adams J; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Palombella VJ; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • McGovern K; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Kutok JL; Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.
  • Wolchok JD; Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory, New York, New York 10065, USA.
  • Merghoub T; Weill Cornell Medical and Graduate Schools, New York, New York 10065, USA.
Nature ; 539(7629): 443-447, 2016 11 17.
Article en En | MEDLINE | ID: mdl-27828943
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Células Mieloides / Inhibidores de Proteínas Quinasas / Puntos de Control del Ciclo Celular / Inhibidores de las Quinasa Fosfoinosítidos-3 / Melanoma Tipo de estudio: Clinical_trials Límite: Animals / Female / Humans / Male Idioma: En Revista: Nature Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Células Mieloides / Inhibidores de Proteínas Quinasas / Puntos de Control del Ciclo Celular / Inhibidores de las Quinasa Fosfoinosítidos-3 / Melanoma Tipo de estudio: Clinical_trials Límite: Animals / Female / Humans / Male Idioma: En Revista: Nature Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos